AMENDMENT NO. 2 to the Multi-Product License Agreement dated 22 August 2012 between LONZA SALES AG and ONCOMED PHARMACEUTICALS, INC 1

EX-10.1 2 omed-ex101_265.htm EX-10.1 omed-ex101_265.htm

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

CONFIDENTIAL

 

Exhibit 10.1

 

AMENDMENT NO. 2

 

to the

 

Multi-Product License Agreement

 

dated 22 August 2012

 

between

 

LONZA SALES AG

 

and

 

ONCOMED PHARMACEUTICALS, INC

 

 

 

 

1

 

 

THIS AMENDMENT is made the 23 day of July 2015

 

BETWEEN

 

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as "Lonza") and

 

ONCOMED PHARMACEUTICALS, INC., incorporated in Delaware whose office is at 800 Chesapeake Drive, Redwood City, CA 94063, USA (hereinafter referred to as “OncoMed”)

 

WHEREAS

 

A.

OncoMed and Lonza entered into a Multi-Product License Agreement dated 22 August 2012 (hereinafter referred to as the “Agreement”), in respect of the use by OncoMed of Lonza’s proprietary System (as defined in the Agreement).

 

B.

Lonza now wishes to clarify the content of Schedule 3 in the Agreement.

 

D.

Lonza and OncoMed now wish to amend the terms of the Agreement.

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, and other good and valuable consideration the receipt of which is hereby acknowledged, it is hereby agreed by the parties to amend the Agreement as follows:

 

1.

The words and phrases defined in the Agreement shall have the same meanings in this Amendment.

 

2.

Schedule 3 of the Agreement is hereby deleted in its entirety and replaced by the Schedule 3 annexed hereto.

 

3.

Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect.


 

1

05Jun15/IS/FA/B17515

 

IN WITNESS WHEREOF the parties have caused this Amendment No. 2 to be executed by their respective representatives thereunto duly authorised as of the day and year first above written.

 

 

/s/ Michael Maskus

Signed for and on behalf of

……………………………………..

LONZA SALES AG

 

 

Michael Maskus

 

Associate Director

 

Commercial Development

 

……………………………………..TITLE

 

 

 

/s/ Nadia Zieger

Signed for and on behalf of

……………………………………..

LONZA SALES AG

 

 

Nadia Zieger

 

Senior Legal Counsel

 

……………………………………..TITLE

 

 

 

EVP, CSO

Signed for and behalf of

……………………………………..TITLE

ONCOMED PHARMACEUTICALS, INC.

 

 

/s/ John Lewicki

 

……………………………………..

 

 

 

 

2

05Jun15/IS/FA/B17515

 

SCHEDULE 3

 

Media and Feeds

 

[***]

 

[***] Four pages in this document have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1

05Jun15/IS/FA/B17515